NP-6A

About Novopyxis

Novopyxis is a private, preclinical-stage biotech firm pioneering a physics- and mathematics-driven platform for drug discovery and delivery. Its core technology applies knot theory and fluid dynamics to design peptide drugs for uncrystallized protein targets and to engineer a painless, needle-free transdermal delivery system. The company's lead therapeutic candidate, NP-6A, is an AT2R agonist for cardiomyopathy, while its Droplette device aims to deliver large-molecule drugs into the skin. With backing from prestigious academic and government partners, Novopyxis is positioning itself at the intersection of computational biology and advanced medical device engineering.

Therapeutic Areas